MMP2 and post-traumatic stress disorder: As an overall conclusion, the above findings stress some potential of MMP-2 as a biomarker for monitoring PTSD severity, particularly in the early recovery phase (Past PTSD ≤ 5 y), where they are linked to overall symptom burden and arousal symptoms.